A final flop signals the bitter end to Circassia’s big plans for allergy R&D
Remember the big plans Circassia {LSE: CIR} had for its allergy drug pipeline when it went public, raising $333 million in 2014 with promises …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
